Medigene AG Logo

Medigene AG

Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.

MDG1 | F

Overview

Corporate Details

ISIN(s):
DE000A40ESG2
LEI:
391200I33JD2DKZGDX06
Country:
Germany
Address:
Lochhamer Straße 11, 82152 Planegg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medigene AG is a clinical-stage immuno-oncology platform company focused on developing differentiated T-cell receptor (TCR)-engineered T cell (TCR-T) therapies to treat solid tumors. The company's proprietary end-to-end platform is designed to generate optimal affinity 3S (sensitive, specific, safe) TCRs that can be applied across various modalities, including TCR-T cell engagers and TCR-natural killer cell therapies. Its pipeline includes candidates such as MDG1015, a 3rd generation TCR-T therapy. According to company announcements, insolvency proceedings for the company's assets were opened by court order on August 1, 2025.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2024-10-16 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-09-18 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-08-14 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 183.1 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-05-06 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 789.0 KB
2024-03-28 00:00
Annual Report
English 9.9 MB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-02-23 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 2.1 KB
2023-08-17 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2023 bis zum 30.0…
German 171.2 KB
2023-04-26 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 665.8 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.4 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2022-08-03 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 183.3 KB
2022-05-02 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 779.5 KB

Automate Your Workflow. Get a real-time feed of all Medigene AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medigene AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medigene AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.